Three lots of buprenorphine hydrochloride, used for pain management, and two lots of labetalol hydrochloride, indicated for blood pressure control in severe hypertension cases, were recalled. The injectable drugs might have incomplete crimp seals, the FDA said May 21.
Pfizer has received one customer complaint about a leaking unit, and there are no reports of adverse events.
“Wholesalers and hospitals with an existing inventory of any of the lots which are being recalled should discontinue use, stop distribution and quarantine the product immediately,” the FDA said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
